Want to join the conversation?
$PFE announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE (palbociclib), oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. The study met primary endpoint by demonstrating improvement in progression-free survival (PFS).
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.